Cardinal Health, Inc. · NYSE:CAH
Cardinal Health — Fact Sheet (January 2023)
1 slide from Cardinal Health's fact sheet, Jan 31, 2023
Slide 1: Humira® biosimilar landscape overview
Humira® biosimilar landscape overview The U.S. biosimilars market is in for a very exciting year in 2023, largely owing to the slate of potentially 10+ biosimilar competitors anticipated to launch against the world’s top selling drug of all time, Humira® (adalimumab)ꝉ. Since first launching in the U